Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2286 - Untreated hormone receptor positive / HER2-negative metastatic breast cancer survival with front-line chemotherapy and maintenance endocrine therapy


11 Sep 2017


Poster display session


Cytotoxic Therapy;  Breast Cancer


Renaud Sabatier


Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365


R. Sabatier, A. Meskine, M.A. Cappiello, J. Extra, C. Tarpin, F. Rousseau, M. Provansal, F. Bertucci, P. Viens, A. Gonçalves

Author affiliations

  • Medical Oncology, Institute Paoli Calmettes, 13274 - Marseille/FR


Abstract 2286


Except some life threatening cases, combination of endocrine therapy and CDK4/6 inhibitors is becoming the standard first line treatment for women with hormone receptor (HR) positive/HER2 negative advanced and metastatic breast cancer (MBC). However cost-effectiveness analyzes are lacking concerning this therapy. As chemotherapy also targets cell cycle we wondered how sequential combination of chemotherapy and maintenance endocrine therapy could be effective as first line treatment for naive HR+/Her2- MBC.


We retrospectively collected from our institutional database (“Institut Paoli-Calmette”, Marseille, France) cases with naive HR+/HER2- MBC. We selected patients treated with chemotherapy plus maintenance endocrine therapy as first line treatment between January 2000 and December 2015. Progression-free survival (PFS) and Overall Survival (OS) were analyzed using the Kaplan-Meier's method. We also conducted univariate (UV) and multivariate analyzes including menopausal status, visceral disease, pathological subtype, and progesterone receptor expression assessed by immunohistochemistry.


A total of 183 female patients were included with a median age at diagnostic of 56,9 years. Most of them were postmenopausal (n = 114, 65.9%) and 108 (59.7%) had visceral metastases. Anthracyclynes-Taxanes combinations were used for 162 patients (88.5%). Median number of chemotherapy cycles was 6. Endocrine therapy was aromatase inhibitors and tamoxifen for 120 (67.8%) and 56 (31.6%) cases, respectively. Median PFS was 33 months [95CI = 25-38] and median OS was 79 months [95CI = 63-101]. In UV analysis pre-menopausal status (HR = 0.58), non-ductal non-lobular subtype (HR = 0.47), and absence of visceral disease (HR = 0.51) were correlated to better OS. All these features remained significant in multivariate analysis. We observed no death related to treatment.


Following these results, and with the issues of cost-effectiveness related to newly approved therapies, first-line chemotherapy plus maintenance endocrine therapy may be considered for untreated HR+/HER2- MBC.

Clinical trial identification

Legal entity responsible for the study

Institut Paoli-Calmettes




R. Sabatier: Travel grants: Pfizer. Consultant: Novartis, Pfizer. Investigator in clinical trials promoted by Novartis and Lilly. F. Bertucci: Investigator in clinical trials promoted by Novartis and Lilly. A. Gonçalves: Consultant: Novartis. Investigator in clinical trials promoted by Novartis and Lilly. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.